Video Experimental Relacionado
Updated: Jan 7, 2026

07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.7K
Selección de pacientes para el tratamiento triple con darolutamida en cáncer de próstata metastásico sensible a la
Teresa Alonso-Gordoa1, Ovidio Fernández-Calvo2, Icíar García-Carbonero3
1Department of Medical Oncology, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
Resumen
No abstract available in PubMed .
Palabras clave:
Cáncer de próstata sensible a la castraciónDarolutamida y sus derivadosCáncer de próstata sensible a las hormonasSelección del pacienteLas neoplasias prostáticas (término MeSH)Modelo de tratamientoTerapia en triplesMás Videos Relacionados
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
10.4K
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
10.5K
Videos de Conceptos Relacionados
Therapeutic Drug Monitoring: Affecting Factors
170
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
170
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K